{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:24:00Z","timestamp":1793831040654,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40263-025-01204-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:52:03Z","timestamp":1752166323000},"page":"903-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7260-8131","authenticated-orcid":false,"given":"Aisling","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"5","key":"1204_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/17582024.2024.2402216","volume":"14","author":"WH Everett","year":"2024","unstructured":"Everett WH, Bucelli RC. Tofersen for SOD1 ALS. Neurodegener Dis Manag. 2024;14(5):149\u201360.","journal-title":"Neurodegener Dis Manag."},{"issue":"9 Suppl","key":"1204_CR2","first-page":"S191","volume":"26","author":"JJ Chen","year":"2020","unstructured":"Chen JJ. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care. 2020;26(9 Suppl):S191\u20137.","journal-title":"Am J Manag Care"},{"issue":"5","key":"1204_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","volume":"32","author":"E Longinetti","year":"2019","unstructured":"Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771\u20136.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"1204_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S, et al. Neurofilaments as biomarkers in neurological disorders\u2014towards clinical application. Nat Rev Neurol. 2024;20(5):269\u201387.","journal-title":"Nat Rev Neurol"},{"issue":"15","key":"1204_CR5","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218\u201326.","journal-title":"Neurology"},{"issue":"15","key":"1204_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/WNL.0b013e3181bc01a4","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive\/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227\u201333.","journal-title":"Neurology"},{"issue":"6415","key":"1204_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59\u201362.","journal-title":"Nature"},{"issue":"6","key":"1204_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14737175.2024.2355983","volume":"24","author":"M Oliveira Santos","year":"2024","unstructured":"Oliveira Santos M, de Carvalho M. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. Expert Rev Neurother. 2024;24(6):549\u201353.","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"1204_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35097565","volume":"2","author":"DW Cleveland","year":"2001","unstructured":"Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2(11):806\u201319.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"1204_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s10038-022-01055-8","volume":"68","author":"N Suzuki","year":"2023","unstructured":"Suzuki N, Nishiyama A, Warita H, et al. Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J Hum Genet. 2023;68(3):131\u201352.","journal-title":"J Hum Genet"},{"issue":"2","key":"1204_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/jnnp-2016-313521","volume":"88","author":"T Bali","year":"2017","unstructured":"Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88(2):99\u2013105.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1204_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1073858414561795","volume":"21","author":"RK Bunton-Stasyshyn","year":"2015","unstructured":"Bunton-Stasyshyn RK, Saccon RA, Fratta P, et al. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. Neuroscientist. 2015;21(5):519\u201329.","journal-title":"Neuroscientist"},{"issue":"8","key":"1204_CR13","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Investig. 2006;116(8):2290\u20136.","journal-title":"J Clin Investig"},{"key":"1204_CR14","unstructured":"Biogen MA Inc. QALSODY\u00ae (tofersen) injection: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/. Accessed 17 June 2025."},{"key":"1204_CR15","unstructured":"European Medicines Agency. Qalsody\u00ae: EU summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/. Accessed 17 June 2025."},{"issue":"11","key":"1204_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA. Tofersen: first approval. Drugs. 2023;83(11):1039\u201343.","journal-title":"Drugs"},{"issue":"4","key":"1204_CR17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS Study. Neurotherapeutics. 2022;19(4):1248\u201358.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"1204_CR18","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Investig. 2018;128(8):3558\u201367.","journal-title":"J Clin Investig"},{"issue":"12","key":"1204_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099\u2013110.","journal-title":"N Engl J Med"},{"key":"1204_CR20","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT03070119. 2017. https:\/\/clinicaltrials.gov\/study\/NCT03070119. Accessed 17 June 2025."},{"issue":"Suppl 1","key":"1204_CR21","first-page":"S1","volume":"68","author":"TM Miller","year":"2023","unstructured":"Miller TM, Cudkowicz M, Genge A, et al. Two-year results from the open-label extension of VALOR: tofersen in adults with SOD1-ALS [abstract plus presentation]. Muscle Nerve. 2023;68(Suppl 1):S1-82.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1204_CR22","first-page":"E533","volume":"93","author":"TM Miller","year":"2019","unstructured":"Miller TM, Cudkowicz ME, Shaw PJ. Safety, PK, PD, and exploratory efficacy in a single and multiple-dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS [abstract no. 6.077]. Neurology. 2019;93(5):E533.","journal-title":"Neurology"},{"issue":"2","key":"1204_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109\u201319.","journal-title":"N Engl J Med"},{"key":"1204_CR24","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","volume":"69","author":"M Wiesenfarth","year":"2024","unstructured":"Wiesenfarth M, Dorst J, Brenner D, et al. Effects of tofersen treatment in patients with SOD1-ALS in a \u201creal-world\u201d setting\u2014a 12-month multicenter cohort study from the German early access program. eClinicalMedicine. 2024;69:102495.","journal-title":"eClinicalMedicine."},{"issue":"3","key":"1204_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.28182","volume":"70","author":"T Meyer","year":"2024","unstructured":"Meyer T, Schumann P, Weydt P, et al. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS\u2014a multicenter observational study over 18 months. Muscle Nerve. 2024;70(3):333\u201345.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1204_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mus.27818","volume":"67","author":"T Meyer","year":"2023","unstructured":"Meyer T, Schumann P, Weydt P, et al. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice. Muscle Nerve. 2023;67(6):515\u201321.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1204_CR27","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1007\/s00415-024-12437-7","volume":"271","author":"M Sabatelli","year":"2024","unstructured":"Sabatelli M, Cerri F, Zuccarino R, et al. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients. J Neurol. 2024;271(8):5177\u201386.","journal-title":"J Neurol"},{"issue":"2","key":"1204_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/acn3.52264","volume":"12","author":"SE Smith","year":"2025","unstructured":"Smith SE, McCoy-Gross K, Malcolm A, et al. Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a \u201creal-world\u201d setting. Ann Clin Transl Neurol. 2025;12(2):311\u20139.","journal-title":"Ann Clin Transl Neurol"},{"key":"1204_CR29","unstructured":"US Food and Drug Administration. Qalsody\u00ae (tofersen): integrated review. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215887Orig1s000IntegratedR.pdf. Accessed 17 June 2025."},{"key":"1204_CR30","unstructured":"European Medicines Agency. Qalsody\u00ae (tofersen): assessment report. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/qalsody-epar-public-assessment-report_en.pdf. Accessed 17 June 2025."},{"issue":"6","key":"1204_CR31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mus.28372","volume":"71","author":"A Lovett","year":"2025","unstructured":"Lovett A, Chary S, Babu S, et al. Serious neurologic adverse events in tofersen clinical trials for amyotrophic lateral sclerosis. Muscle Nerve. 2025;71(6):1006\u201315.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1204_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16264","volume":"31","author":"P Van Damme","year":"2024","unstructured":"Van Damme P, Al-Chalabi A, Andersen PM, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). Eur J Neurol. 2024;31(6):e16264.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1204_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ana.26860","volume":"95","author":"M Benatar","year":"2024","unstructured":"Benatar M, Ostrow LW, Lewcock JW, et al. Biomarker qualification for neurofilament light chain in amyotrophic lateral sclerosis: theory and practice. Ann Neurol. 2024;95(2):211\u20136.","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"1204_CR34","first-page":"S16","volume":"66","author":"TM Miller","year":"2022","unstructured":"Miller TM, Glass JD, Cudkowicz M, et al. Statistical model of the relationship of neurofilament with clinical function in the VALOR phase 3 study of tofersen in adults with SOD1-ALS [abstract no. 32]. Muscle Nerve. 2022;66(Suppl 2):S16.","journal-title":"Muscle Nerve"},{"issue":"11","key":"1204_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1204_CR36","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1212\/WNL.0000000000004960","volume":"90","author":"M Benatar","year":"2018","unstructured":"Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565\u201374.","journal-title":"Neurology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01204-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:46:16Z","timestamp":1757220376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01204-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01204-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Aisling McGuigan and Hannah A. Blair are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}